Indian Endocrinologists Warn: Weight Loss Drugs Need Dietary Plan to Avoid Muscle Loss
Leading Indian endocrinologists have issued a consensus statement stressing that diet must be considered as important as medication when using GLP-1 receptor agonists for weight loss. The guidance, published in the journal Obesity Pillars, addresses the growing use of drugs like semaglutide and tirzepatide for obesity and Type 2 diabetes management in India.
The expert panel, co-authored by Dr V Mohan, Chairman of Dr Mohan’s Diabetes Specialities Centre in Chennai, warns that without structured nutritional support, patients may lose muscle and bone mass instead of fat, develop vitamin and mineral deficiencies, and struggle to maintain weight loss after stopping the drugs.
GLP-1 medicines work by reducing appetite, increasing fullness, and delaying stomach emptying. While effective for weight management, they also significantly reduce overall food intake. The panel notes that this can lead to insufficient consumption of protein, vitamins, minerals, and fluids.
“Indians need more attention to nutrition because we eat too many carbs, have less protein, eat unhealthy fats and very little of healthy fats. We are highly deficient in vitamin D, vitamin B12 and iron. We have excess visceral fat and lower muscle mass,” Dr Mohan explained.
The consensus identifies five major challenges during GLP-1 therapy: gastrointestinal side effects (nausea, vomiting, constipation, diarrhoea), nutritional deficiencies (especially vitamins D and B12, iron, calcium, magnesium, zinc), loss of lean muscle mass, bone health reduction, and weight regain after discontinuation.
Studies reviewed by the panel indicate that nutritional deficiencies nearly double between six and 12 months after starting GLP-1 therapy, underscoring the need for regular nutritional assessment. Approximately one-quarter of weight lost may come from muscle rather than fat, particularly in patients with inadequate protein intake or low physical activity. This is especially concerning for older adults and Asian Indians, who naturally have lower baseline muscle mass and higher risk of sarcopenia.
Bone health is also flagged: rapid weight loss can reduce bone mineral density, though evidence is mixed. The consensus recommends monitoring bone health in high-risk patients and ensuring adequate calcium and vitamin D intake. Finally, weight regain after stopping therapy is common; proper dietary habits during treatment may help sustain loss.
The panel advises that all patients on GLP-1 drugs receive individualised dietary counselling, with emphasis on adequate protein (1.2–1.5 g per kg body weight), healthy fats, complex carbohydrates, and micronutrient supplementation as needed. The goal is to preserve muscle mass, maintain bone density, and support long-term weight management.
